Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine

Radiolabelled cytokines and chemokines are a group of radiopharmaceuticals that, by highlighting in vivo the binding to specific high-affinity receptors expressed on selected cell populations, allow the molecular and functional characterisation of immune-mediated processes Recently, several authors have described the use of radiolabelled cytokines and chemokines not only for imaging of inflammation and infection, but also as an approach to study in vivo the biology of primary and metastatic cancer cells. The latter avenue of research has been pursued particularly to help oncologists in therapeutic decision making and to follow up the efficacy of new immune therapies. In this paper we describe the characteristics of cytokines and chemokines, focussing on their role as radiopharmaceuticals for the imaging of cancer cells in vivo, a new challenge for molecular nuclear medicine.     

Quality assurance and nuclear medicine: the challenge of change

There is increasing emphasis on quality assurance in nuclear medicine instigated, in part, by changing JCAH standards. Our response to this challenge has led to a program combining physician monitoring of 5% and generic monitoring of 100% of nuclear medicine studies. The described approach is reasonable, easily achievable, and improves nuclear medicine care.     

Xenon-127m: a new radionuclide for applications in nuclear medicine

Xenon-127m (127mXe) emits two gamma rays in cascade, with half-life of 69.2 +/- 0.9 sec. The first has the energy of 172.5 keV, and is emitted from the nucleus in 38% of the decays. The second gamma ray has the energy of 124.8 keV and is emitted from the nucleus in 69% of the disintegrations. Together they furnish 107 easily collimated gamma rays per 100 decays. Xenon-127m is generated readily by bombarding nearly saturated aqueous solutions of sodium or potassium iodide with 14-MeV protons. The 127mXe is swept out continuously, as it is produced, by bubbling helium upward through the solutions. Up to approximately 100 mci/l are obtained from the resulting mixture of gases. The 127mXe + helium is admixed with about five volumes of air (or oxygen) and then driven continuously to a scintillation camera located approximately 200 yd distant. When the mixture of gases is inhaled, high quality images of the lungs are obtained by means of an Anger scintillation camera.     

Krypton-79m: a new radionuclide for applications in nuclear medicine

Krypton-79m emits 130-keV gamma rays in 27 +/- 1% of its disintegrations and decays with a half-life of 50 +/- 3 sec. It is generated readily by bombarding nearly saturated aqueous solutions of bromide salts, or bromoform, with 14-MeV protons. The 79mKr is swept out continuously as it is produced by bubbling helium upward through the liquids. Up to 200 mCi per I are obtained of the resulting mixture of gases. The 79mKr + helium is mixed with about five volumes of air and then driven continuously through a small-bore tube to an Anger scintillation camera located approximately 200 yards away. The rate of flow is adjusted so that the amounts of 13-sec 81mKr and of 35-hr 79Kr are inconsequential at the time and point of use. When the gases are inhaled, good images of the lungs are obtained with an Anger scintillation camera. The trachea and bronchi commonly are revealed also.     

Compartment modelling in nuclear medicine: a new program for the determination of transfer coefficients

In many investigations concerning transport/exchange of matter in a natural system, e.g. functional studies in nuclear medicine, it is advantageous to relate experimental results to a model of the system. This paper presents a new computer program for the determination of linear transfer coefficients in a compartment model from experimentally observed time-compartment content curves. The program performs a least-square fit with the specified precision of the observed values as weight factors. The resulting uncertainty in the calculated transfer coefficients may also be assessed. The application of the program in nuclear medicine is demonstrated and discussed.